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The grand challenge of increasing productivity within the pharmaceutical sector 1 has led to the automation of many parts of the drug discovery process 2 . For example, high-throughput screening of large compound collections is widely exploited to generate a series of 'hit molecules' that can provide starting points for a drug discovery programme 3 . In addition, arrays of molecules are often synthesized and purified using automated approaches 4 , reducing the volume of labour-intensive tasks required. Currently, however, automation within discovery workflows almost always focuses on individual stages of the discovery process (Fig. 1) .
The quest to improve the productivity of drug discovery, however, is at odds with the aspiration to increase chemical and biological innovation. For example, designing drugs against future biological targets, such as protein-protein interactions and large macromolecular complexes, is likely to bring new scientific challenges and to require different classes of ligands 5 . The challenge of discovering such ligands is heightened by the vastness of the drug-relevant chemical space; although drug discovery 10, 11 , medicinal chemists are focusing on more lipophilic and flat compounds 12, 13 . This behaviour is largely driven by current discovery workflows that are underpinned by a remarkably narrow (though gradually increasing) 13 toolkit of robust reaction types [14] [15] [16] [17] . The introduction of new ultrahigh-throughput chemical technologies, such as DNA-encoded libraries 18 , can greatly increase the number of compounds explored, although they tend to limit the number of reaction classes used. How, then, can the productivity of drug discovery be improved while enabling currently challenging targets to be addressed?
In this Perspective, we describe progress towards the automation and integration of adjacent stages within discovery workflows. We deliberately focus on integrated approaches that have already been exploited in discovery rather than on isolated methods that have the potential to be integrated into discovery workflows. To provide context, the value of the integrated approaches is illustrated using specific case studies.
Integrated discovery platforms
The automation of chemical synthesis 4, 19 can increase the efficiency and reproducibility of synthetic chemistry within discovery workflows. Although the adoption of parallel chemical syntheses is widespread, compound purification is almost always performed in series. This bottleneck is imposed by the technologies that are widely adopted for purification (such as mass-directed high-performance liquid chromatography (HPLC)) and by the estimates vary, extrapolation from the Chemical Universe Database GDB-17 (a database of enumerated molecules with up to 17 heavy atoms) estimated that there are ~10 33 possible molecules with up to 36 heavy atoms 6 . Nonetheless, chemists' historical exploration of chemical space has been highly uneven and unsystematic 7 , leading to a lack of scaffold diversity in explored medicinal chemistry space 8 and clinically approved drugs 9 . Furthermore, despite overwhelming recognition of the importance of molecular properties in Streamlining bioactive molecular discovery through integration and automation
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Abstract | The discovery of bioactive small molecules is generally driven via iterative design-make-purify-test cycles. Automation is routinely harnessed at individual stages of these cycles to increase the productivity of drug discovery. Here, we describe recent progress to automate and integrate two or more adjacent stages within discovery workflows. Examples of such technologies include microfluidics, liquid-handling robotics and affinity-selection mass spectrometry. The value of integrated technologies is illustrated in the context of specific case studies in which modulators of targets, such as protein kinases, nuclear hormone receptors and protein-protein interactions, were discovered. We note that to maximize impact on the productivity of discovery , each of the integrated stages would need to have both high and matched throughput. We also consider the longer-term goal of realizing the fully autonomous discovery of bioactive small molecules through the integration and automation of all stages of discovery. ). Many reaction classes (including multiphase reactions) have been automated, and the automation of the dominant reactions within the medicinal chemistry toolkit (such as heteroatom functionalizations and metal-catalysed cross-couplings) is widespread. Furthermore, automated multistep synthesis is possible, for example, in the synthesis of β-amino acid and γ-amino acid derivatives using several different reaction classes 22 .
Although the broader context of automated synthesis is relevant to this Perspective, we focus here on approaches in which the automation of synthesis has been integrated with adjacent stages within discovery workflows.
Integration of reaction optimization and synthesis. The molecules that are designed within medicinal chemistry programmes generally need to be prepared from polar and functionalized substrates 11, 23 . Such reactants tend to perform systematically poorly in chemical reactions, resulting in a substantial drift in the log P value -the octanol-water partition coefficient -between designed and produced arrays 23 . Accordingly, the properties of produced compounds tend to be shifted from those that were originally designed. Therefore, several teams [24] [25] [26] [27] [28] have developed high-throughput approaches to optimize reactions within medicinal chemistry workflows. The ability to explore many different reaction parameters 29 rapidly while using small amounts of material can markedly increase the value of specific reaction classes in discovery applications. Although published examples are essentially limited to the standard medicinal chemistry toolkit (Table 1) , these high-throughput approaches should broaden the range of reactions that can be harnessed for molecular discovery. For example, C-H functionalizations at sp 3 -hybridized carbons offer great promise 17 for drug discovery, but such reactions remain largely untapped 30, 31 . These reactions could allow complementary growth vectors to be used, allowing new chemical space to be explored during lead optimization. Notably, high-throughput experimentation can also enable the initial discovery of new catalytic reactions 32 and the identification of transformations with high functional group tolerance 33 . The high-throughput optimization of palladium-catalysed cross-couplings leading to highly functionalized products has been conducted on the nanomolar scale 27 ( Fig. 2aa) . Metal-catalysed couplings, including Suzuki-Miyaura and BuchwaldHartwig reactions, have received particular attention in this area because substantial optimization is often needed for each pair of substrates. The study focused on palladium-catalysed C-C, C-O and C-N bond-forming reactions involving combinations of 12 polar nucleophiles and 8 complex electrophiles. Initial attempts to synthesize the 96 possible products in a 96-well format on a 500 μmol scale resulted in 54 successful reactions (Fig. 2aa ).
In the optimization study, arrays of reactions were set up in plastic 1,536-well plates using a nanolitre liquid-handling robot. The reactions were performed on an ~100 nmol scale in 1.0 μl dimethyl sulfoxide (DMSO) at room temperature without agitation, and the outcomes were determined using mass spectrometry. Attention was focused on 32 of the nucleophile-electrophile combinations (such as the aryl chloride 1 and the alcohol 2) that had failed during the initial synthesis. These 32 combinations were each subjected to 48 different conditions (that is, 6 catalysts and 8 organic superbases), leading to a total of 1,536 test reactions. For 21 of the 32 combinations, the required product mass was detected (as exemplified by 3); 16 of these 21 products were isolated after scale-up to 500 μmol. For 6 of the remaining failed reactions, 48 combinations of reagent stoichiometry and catalyst loading were then explored, and conditions that led to product synthesis were identified in 5 cases. Thus, from these 2 high-throughput experiments, 21 complex products that had previously eluded synthesis could be prepared (Fig. 2ab) . Finally, to demonstrate that reaction optimization on the nanomolar scale can inform the development of practical gram-scale syntheses, it was shown that conditions identified on a 0.02 mg scale enabled the efficient coupling of the chloride 4 and the amine 5 to yield 6 on 25 mg and 1 g scales (Fig. 2ac) .
In another reaction optimization study, an automated flow-based platform enabled both nanomolar-scale reaction screening and micromolar-scale synthesis 28 ( Fig. 2b) . Although the approach is inherently serial in nature, high-throughput operation (>1,500 per day) was possible. The 5,760 reaction conditions were explored by injection of the appropriate components into the same flow segment and analysis of the reaction outcome by liquid chromatography-mass spectrometry (LC-MS) (Fig. 2ba) . Furthermore, it was demonstrated that the required product could be prepared on a micromolar scale on the platform through repetition of the optimized reaction and on a 50-200 mg scale in standard flow and batch modes (Fig. 2bb) .
The integration of high-throughput reaction optimization into discovery workflows is particularly valuable when bespoke conditions are required for each specific combination of reactants. High throughput is possible either by operation in parallel (in batch mode) or in series (for example, in flow mode with a fast cycle time). To achieve full impact, it will be necessary to exploit these platforms to harness a wider range of reaction classes within discovery workflows.
Integration of synthesis and biological evaluation. Several platforms that integrate automated synthesis and biological evaluation have been developed and exemplified in bioactive molecule discovery [34] [35] [36] [37] [38] [39] [40] [41] [42] (Table 2 ).
These platforms generally have a chemical reactor module, an offline compound processing unit and a biological testing module. Inherently modular systems can enable flexible configuration to meet the needs of specific discovery projects.
The throughput of these platforms depends on both the timescale and the parallel or serial nature of the activities that are performed. For example, in a programme focused on identifying compounds that bind the Polycomb protein EED 36 , batch synthesis in vials (in parallel), mass-directed HPLC purification (in series) and a plate-based biochemical assay (in parallel) enabled the synthesis and evaluation of 22 compounds in ~24 h. The throughput of a programme The immobilized protein was stable up to 6 months.
f Solvent removal and manual preparation were carried out before screening. Direct injection of product aliquot into the FAC assay was also possible after appropriate dilution. Fig. 3 | Platforms that integrate synthesis and biological evaluation to enable the discovery of bioactive small molecules. A | Application of an integrated platform in the discovery of beta-secretase 1 (BACE1) inhibitors. Aa | Schematic illustration of the integrated workflow. The on-chip assay technology integrated a thin capillary and a glass chip that enabled enzyme activity assessment in flow after combining ligand, enzyme and substrate streams. Ab | Exemplar ligands (7 and 8) that were synthesized and tested against BACE1 are shown; the on-chip biological evaluation was validated using a plate-based assay and confirmed the low nanomolar activity of these ligands. B | Integration of nanoscale synthesis and affinity ranking in the discovery of serine/threonine-protein kinase CHK1 (CHK1) inhibitors. Ba | Schematic illustration of the integrated workflow. An array of 384 target compounds that might be prepared by coupling the 2-bromothiazole 9 with 384 different nucleophiles was designed. The 384 cross-couplings were performed using four prioritized reaction conditions for each reaction class; together, these conditions enabled the preparation of 345 of the 384 targeted products. Pools of 12-24 reaction products were incubated with CHK1 and assessed by affinity-selection mass spectrometry , enabling affinity ranking. Bb | Exemplar CHK1 inhibitors (for example, 10a-c) that were discovered and the activity of which was confirmed after resynthesis. DMF, N,N-dimethylformamide; HPLC-MS, high-performance liquid chromatography-mass spectrometry ; HRMS, high-resolution mass spectrometry ; IC 50 focused on identifying inhibitors of dipeptidyl peptidase 4 (DPP4) was similar (~2 h per compound) and was driven by synthesis in a microfluidic reactor (in series), HPLC purification (in series) and a plate-based biochemical assay (in parallel) 37 . In-line continuous flow technologies can enable multiple stages within drug discovery workflows to be integrated. For example, affinity chromatography has been exploited to immediately determine the affinity of synthesized compounds for a target protein 38, 39 . The approach is particularly valuable when in-line purification is possible, as has been demonstrated in the discovery of ligands for human serum albumin 39 . In that work, it was also demonstrated that manual operations could be omitted if reaction products were diluted and directly injected onto the affinity column 39 . Integrated flow technologies have been exploited in the discovery of inhibitors of the protease beta-secretase 1 (BACE1) 40 ( Fig. 3a) . The on-chip assay technology integrated a thin capillary (to generate a ligand concentration gradient over several orders of magnitude) and a glass chip that enabled activity assessment in flow after combining ligand, enzyme and substrate streams (Fig. 3aa) . Measurement of the fluorescence at different locations on the chip enabled determination of the dose-dependent activity at 100 different ligand concentrations. The use of flow technologies at all stages enabled each compound to be prepared, purified and evaluated in series in ~1 h. The approach enabled the structure-activity relationship (SAR) of a series of inhibitors (for example, 7 and 8) to be defined (Fig. 3ab) .
A platform that integrated reaction optimization, library synthesis and affinity ranking was exploited in the discovery of serine/threonine-protein kinase CHK1 (CHK1; also known as CHEK1) inhibitors 41 ( Fig. 3b ). An array of 384 target compounds was designed that would be accessible via coupling of the 2-bromothiazole 9 with 384 different nucleophiles: 48 thiols for C-S cross-couplings; 32 alkynes and 80 boronates for C-C cross-couplings; 64 alcohols for C-O cross-couplings; and 32 amides, 32 sulfonamides and 96 amines for C-N cross-couplings. Initially, four productive reaction conditions were identified for each class of nucleophile. The 384 cross-couplings were then each performed on an ~100 nmol scale under the 4 reaction conditions (Fig. 3ba) . By exploiting the best of the 4 alternative conditions, 345 of the 384 targeted products could be prepared (compared with just 158 products using a single reaction condition). Pools of 12-24 reaction products were then incubated with the target protein and eluted through a size-exclusion column to remove unbound compounds; the identity of the bound compounds was then determined by mass spectrometry. By varying the concentration of the target protein, it was possible to rank the ligands by their affinity for the target protein. The activity of a range of compounds (for example, 10a-c) was confirmed after their resynthesis on a 50 μmol scale (Fig. 3bb) .
The efficiency of experimentally exploring predefined regions within chemical space can be increased using active learning models 43 . Such models are initially built from training data and are continuously refined in real time in light of the activity of the new compounds that are synthesized. In a programme to discover tyrosine-protein kinase ABL1 (ABL1) kinase inhibitors 42 ( Fig. 4 ; Table 2 ), active learning was integrated with microfluidic-based synthesis, purification and biochemical evaluation to drive molecular discovery. A model was initially constructed on the basis of the biological activity of 32 known kinase inhibitors. Using ponatinib as a template, potential Asp-Phe-Gly (DFG) binding motifs and hinge-binding heterocycles were combined to define a virtual library. Ten aryl iodides (with a potential DFG-binding motif) and 27 alkynes (with a potential hinge-binding motif) were prepared, giving a total of 270 potential Sonogashira coupling products. To establish SAR quickly and to accelerate refinement of the model, 29 diverse products were targeted in the first round (Mode A, see Fig. 4 ), of which 22 were successfully prepared and evaluated. The aim of the second round was to optimize potency within the previously identified hot spots (Mode B, see Fig. 4) ; 20 compounds were targeted, of which 14 were successfully investigated. In the final round, a combination of the two strategies was used. Overall, in a total of 90 cycles, 64 new compounds (of the 270 possibilities) were synthesized and evaluated with a successful completion rate of 71%. The self-refining active learning model avoided the need for exhaustive SAR studies, and 31 novel inhibitors with a half-maximal inhibitory concentration (IC 50 ) of <50 nM (for example, 11 and 12) were identified in 135 h of machine time.
Although several platforms that integrate small-molecule synthesis and biological evaluation have been developed, throughput is rarely matched at all stages, and some manual operations (for example, purification, characterization, quantification and solvent reformatting) are often required. In particular, compound purification is usually performed in series, even when synthesis and biological evaluation are possible in parallel, and this can interrupt otherwise integrated workflows. Thus, approaches that enable parallel compound purification, or the preliminary assessment of binding using partially purified reaction products 44 , may have particular value in integrated discovery workflows.
Function-directed discovery Current discovery workflows focus on the design of specific molecules that are then deliberately prepared and evaluated. The narrow toolkit of robust reactions that may be accommodated within such workflows can inadvertently limit the diversity of chemical space that can be explored. In stark contrast to this approach, the emergence of natural products is structure-blind 45, 46 and driven by the functional benefit to the host organism. Notably, the diverse functions of natural products have inspired the discovery of around a third of all the US Food and Drug Administration (FDA)-approved drugs 47 . Activity-directed synthesis (ADS) is a function-directed approach that borrows some concepts from the emergence of biosynthetic pathways that yield natural products 48, 49 . A conceptually similar approach -synthetic fermentation -has also been developed, and it was exemplified in the discovery of β-peptide-based inhibitors of hepatitis C virus (HCV) NS3/4A protease 50 . ADS and synthetic fermentation are complementary to dynamic combinatorial chemistry, in which the most potent ligands are favoured via synthesis under thermodynamic control in the presence of a target protein 51 . In ADS, inherently promiscuous reactions that have many possible outcomes are deliberately harnessed to facilitate the discovery of unexpected bioactive chemotypes. Initially, a reaction array is designed in which the components (substrate or substrates, catalysts and solvents) used in the reactions are widely varied. After catalyst scavenging, the crude reaction products are evaporated, dissolved in DMSO and evaluated for biological function. The design of reaction arrays in subsequent rounds is informed by reactions that are known to yield bioactive products. The identity of the responsible bioactive ligands is revealed only after scale-up of volUme 2 | AUGUST 2018 | 179 the promising reactions, purification and functional validation.
ADS was used to discover agonists of the androgen receptor (Fig. 5) . Here, metal-catalysed carbenoid chemistry was exploited both intramolecularly 48 and intermolecularly 49 . For the intramolecular reactions, 12 substrates were designed that contained a diazo group -the 4-cyano-3-trifluoromethyl phenyl fragment known to target androgen receptors -and a potentially reactive side chain. It was shown retrospectively that ADS can drive optimization of both the ligand structure and the corresponding synthetic route ( Fig. 5c ). For example, the bioactive β-lactam 14 was produced from 13 in round 1, and its yield was optimized in round 2 through exploitation of a wider range of catalysts and solvents. Finally, introduction of the related substrate 15 in round 3 enabled identification of the related agonist 16. Over the 3 rounds of ADS, 336 reactions were performed, but only 3 bioactive ligands needed to be purified and structurally elucidated. Crucially, the chemotypes discovered had no previously annotated androgen receptor activity, and the most potent ligands identified had sub-micromolar activity. It was subsequently demonstrated that the use of intermolecular reactions can expand the chemical space explored and facilitate the discovery of further novel and unexpected bioactive chemotypes (for example, 18 and 19, which were prepared from 17) 49 ( Fig. 5d ).
Function-directed approaches have the potential to drive the discovery of bioactive small molecules. Such approaches do not require structural information, and they can deliberately harness promiscuous reactions to enable diverse regions within chemical space to be explored. All parts of the discovery workflow, namely, the design and implementation of reaction arrays and the scavenging and evaluation of the reaction products, can be performed in parallel.
Crucially, resources are then focused only on scaling up and evaluating the products of prioritized reactions that yield active products. Although function-directed approaches have been exemplified against only a few targets, it has been shown that unexpected chemotypes can emerge in parallel with an associated synthetic route.
Conclusions and outlook
Important progress has been made towards the fully integrated discovery of bioactive small molecules. It has been shown that adjacent stages within design-makepurify-test-analyse cycles can be integrated and that this can facilitate the discovery of novel functional molecules. Crucially, the integration of reaction optimization into discovery workflows has the potential to considerably expand the chemical space that can be explored. Specifically, the ability to optimize the synthesis of each target molecule should encourage the adoption of a wider reaction toolkit (for example, C-H functionalizations) within discovery programmes. To maximize the impact on the productivity of discovery, the throughput of the integrated stages within workflows should be high and matched.
To avoid the interruption of otherwise integrated workflows, technologies for parallel purification, as well as those that enable the activity of partially purified reaction products to be assessed, may have particular value. In addition, we note that the integration of a wider range of measurements on synthetic productsfor example, measurements that capture selectivity and physicochemical properties as well as affinity for the target proteinwould be valuable in informing subsequent molecular design. There are isolated examples of discovery programmes in which reaction optimization, synthesis and biological evaluation have been fully integrated. Perhaps unsurprisingly, the technology underpinning these platforms is highly varied. The discovery of CHK1 inhibitors integrated reaction optimization (via HPLC-MS) and assessment of the binding of unpurified reaction products (using affinity-selection mass spectrometry) 41 ( Fig. 3b) . Although relatively standard coupling chemistry was exploited, the technology platform may enable a wider reaction toolkit to be exploited in discovery. The ADS of androgen receptor agonists exploited metal-catalysed reactions with many possible outcomes 49, 50 (Fig. 5) . Here, biological evaluation of the crude reaction products enabled both the ligand structure and the corresponding synthetic route to be optimized in parallel.
The realization of autonomous bioactive molecular discovery would require the integration of technologies to drive all stages within iterative cycles of molecular design, synthesis and evaluation. In addition to the experimental platforms described in this Perspective, computational approaches would be required to enable the design of follow-up compounds (and their corresponding syntheses). Computational tools are now available to support the prediction of the outcome of chemical reactions 52, 53 and the design of follow-up molecules with desirable properties (including affinity, selectivity and physicochemical profiles) 2, 43, 54, 55 . However, the integration of all these components remains a challenge that needs to be met to realize fully autonomous molecular discovery. Published online 27 July 2018
